18F-FDG PET/CT and PET/MRI perform equally well in cancer patients: Evidence from studies in more than 2300 patients.

18F-FDG PET/CT and PET/MRI perform equally well in cancer patients: Evidence from studies in more than 2300 patients.

J Nucl Med. 2016 Jan 7;

Authors: Spick C, Herrmann K, Czernin J

Abstract
(18)F-FDG-PET/CT has become the reference standard in oncologic imaging against which the performance of other imaging modalities is measured. The promise of PET/MRI includes multi-parametric imaging to further improve diagnosis and phenotyping of cancer. Rather than focusing on these capabilities many investigators have however examined whether (18)F-FDG-PET combined with mostly anatomic MRI improves cancer staging and restaging. Following a description of PET/MRI designs, and a discussion of technical and operational issues we review the available literature to determine whether cancer assessments are improved with PET/MRI. The available data show that PET/MRI is feasible and performs equally well as PET/CT in most cancers. Diagnostic advantages may be achievable in prostate cancer and in bone metastases while disadvantages may exist in lung nodule assessments. We conclude that (18)F-FDG PET/MRI and PET/CT provide comparable diagnostic information when MRI is simply used to provide the anatomical framework. Thus, PET/MRI could be used in lieu of PET/CT if this approach becomes economically viable and if reasonable workflows can be established. Future studies should explore the multi-parametric potential of MRI.

PMID: 26742709 [PubMed - as supplied by publisher]

from #PubMed 3 via ola Kala on Inoreader http://ift.tt/1MYJkhc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IVNzit
via IFTTT